NF 6505

Drug Profile

NF 6505

Latest Information Update: 17 Jan 2001

Price : $50

At a glance

  • Originator Japan Energy Corporation
  • Developer Daiichi Fine Chemical; Japan Energy Corporation
  • Class Antithrombotics; Oligopeptides
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Venous thrombosis

Most Recent Events

  • 17 Jan 2001 Discontinued-Preclinical for Venous thrombosis in Japan (Unknown route)
  • 22 Aug 1997 New profile
  • 22 Aug 1997 Preclinical development for Venous thrombosis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top